Due to a flaw in the devices that can cause the batteries to wear out. Boston Scientific Corp. has recalled some of its defibrillators, the FDA confirmed on its website.
A posting on the FDA’s website detailed that on April 5, Natick, Mass.-based Boston Scientific recalled approximately 73,000 implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators, due to a flaw in the devices that can cause the batteries to wear out sooner than expected.
The company said that most patients would not be affected by the recall, but should contact their physicians about what steps to take next.
As of March 30, the company said it confirmed 19 field events with Guidant’s devices, mostly related to premature battery depletion. There were no serious injuries or deaths reported.
maintains a cardiac rhythm-management unit in Arden Hills
Boston Scientific (NYSE: BSX) maintains a cardiac rhythm-management unit in Arden Hills that it acquired with Guidant Corp. It also has a Maple Grove facility that focuses on interventional cardiology technology, such as stents.